Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 23;107(1):58–76. doi: 10.3324/haematol.2020.260331

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2022 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 6. — Combined inhibition of BCL-2 and MCL-1 has strong anti-leukemia activity and prolongs survival in a patient-derived xenograft model of acquired venetoclax/decitabine-resistant acute myeloid leukemia. (A) Patient-derived xenograft (PDX) model and experimental scheme. (B) Circulating human CD45⁺ (hCD45⁺) cells in mouse peripheral blood (PB) samples obtained from each treatment group on treatment day (d) 18. (C) hCD45⁺ cells in mouse bone marrow (BM) samples obtained from each treatment group on treatment d 25. (D) hCD45⁺ cells in mouse spleens and spleen sizes of each treatment group on treatment d 25. hCD45⁺ cells were measured by flow cytometry. (E) Survival curves. (F) BM leukemia cell clusters based on the expression of cell surface markers and viable leukemic cells in various cell populations on treatment d 25 in each treatment group as determined by cytometry by time of flight (CyTOF). *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001. Results are expressed as the mean ± standard error of the mean. Survival data were analyzed using the log-rank test. Con: control; VEN: venetoclax; 5991: AZD5991; 4573: AZD4573.